Abstract
Heart failure management is complex and constantly evolving. The American College of Cardiology and the American Heart Association (ACC/AHA) last issued evidence-based guidelines in 2013, and since then, new drugs and devices have been developed. This review presents an evidence-based approach to current heart failure management.
Copyright © 2016 Cleveland Clinic.
MeSH terms
-
Adrenergic beta-Antagonists / therapeutic use
-
Aminobutyrates / therapeutic use
-
Angiotensin Receptor Antagonists / therapeutic use
-
Angiotensin-Converting Enzyme Inhibitors / therapeutic use
-
Biphenyl Compounds
-
Cardiac Resynchronization Therapy Devices
-
Defibrillators, Implantable
-
Digoxin / therapeutic use
-
Diuretics / therapeutic use
-
Drug Combinations
-
Evidence-Based Medicine
-
Exercise
-
Heart Failure / physiopathology
-
Heart Failure / therapy*
-
Heart-Assist Devices
-
Humans
-
Mineralocorticoid Receptor Antagonists / therapeutic use
-
Natriuretic Peptide, Brain / blood
-
Peptide Fragments / blood
-
Practice Guidelines as Topic
-
Systole
-
Tetrazoles / therapeutic use
-
Valsartan
Substances
-
Adrenergic beta-Antagonists
-
Aminobutyrates
-
Angiotensin Receptor Antagonists
-
Angiotensin-Converting Enzyme Inhibitors
-
Biphenyl Compounds
-
Diuretics
-
Drug Combinations
-
Mineralocorticoid Receptor Antagonists
-
Peptide Fragments
-
Tetrazoles
-
pro-brain natriuretic peptide (1-76)
-
Natriuretic Peptide, Brain
-
Digoxin
-
Valsartan
-
sacubitril and valsartan sodium hydrate drug combination